Found: 32
Select item for more details and to access through your institution.
Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G<sub>2</sub>/M cell cycle arrest and apoptosis.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 433, doi. 10.1007/s00280-008-0888-2
- By:
- Publication type:
- Article
Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 445, doi. 10.1007/s00280-008-0892-6
- By:
- Publication type:
- Article
A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 455, doi. 10.1007/s00280-008-0893-5
- By:
- Publication type:
- Article
The x cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 463, doi. 10.1007/s00280-008-0894-4
- By:
- Publication type:
- Article
Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 473, doi. 10.1007/s00280-008-0895-3
- By:
- Publication type:
- Article
Tumor specific cytotoxicity of beta-glucosylceramide: structure-cytotoxicity relationship and anti-tumor activity in vivo.
- Published in:
- 2009
- By:
- Publication type:
- Journal Article
Tumor specific cytotoxicity of β-glucosylceramide: structure–cytotoxicity relationship and anti-tumor activity in vivo.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 485, doi. 10.1007/s00280-008-0896-2
- By:
- Publication type:
- Article
Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 497, doi. 10.1007/s00280-008-0897-1
- By:
- Publication type:
- Article
Application of prolonged microdialysis sampling in carboplatin-treated cancer patients.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Application of prolonged microdialysis sampling in carboplatin-treated cancer patients.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 509, doi. 10.1007/s00280-008-0898-0
- By:
- Publication type:
- Article
Attenuation of skeletal muscle atrophy in cancer cachexia by d-myo-inositol 1,2,6-triphosphate.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 517, doi. 10.1007/s00280-008-0899-z
- By:
- Publication type:
- Article
Evaluation of the antitumoral effect of dihydrocucurbitacin-B in both in vitro and in vivo models.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 529, doi. 10.1007/s00280-008-0901-9
- By:
- Publication type:
- Article
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 539, doi. 10.1007/s00280-008-0902-8
- By:
- Publication type:
- Article
Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 549, doi. 10.1007/s00280-008-0903-7
- By:
- Publication type:
- Article
A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 557, doi. 10.1007/s00280-008-0904-6
- By:
- Publication type:
- Article
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
- Published in:
- 2009
- By:
- Publication type:
- Journal Article
Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 565, doi. 10.1007/s00280-008-0907-3
- By:
- Publication type:
- Article
Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 575, doi. 10.1007/s00280-008-0908-2
- By:
- Publication type:
- Article
Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
- Published in:
- 2009
- By:
- Publication type:
- Journal Article
Pegylated liposomal doxorubicin (CAELYX<sup>®</sup>) in patients with advanced ovarian cancer: results of a German multicenter observational study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 585, doi. 10.1007/s00280-008-0909-1
- By:
- Publication type:
- Article
Role of frequency and mechanical index in ultrasonic-enhanced chemotherapy in rats.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 593, doi. 10.1007/s00280-008-0910-8
- By:
- Publication type:
- Article
The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 601, doi. 10.1007/s00280-008-0911-7
- By:
- Publication type:
- Article
RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 607, doi. 10.1007/s00280-008-0912-6
- By:
- Publication type:
- Article
Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
- Published in:
- 2009
- By:
- Publication type:
- Journal Article
Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase ( DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 615, doi. 10.1007/s00280-009-0970-4
- By:
- Publication type:
- Article
Prolonged accumulation of high-dose methotrexate in a case with large liver cysts.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 619, doi. 10.1007/s00280-009-0982-0
- By:
- Publication type:
- Article
Improved survival in patients with breast rhabdoid tumors with multi-agent adjuvant chemotherapy combined with irradiation.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 623, doi. 10.1007/s00280-009-0989-6
- By:
- Publication type:
- Article
MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 629, doi. 10.1007/s00280-009-1004-y
- By:
- Publication type:
- Article
Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 635, doi. 10.1007/s00280-009-1010-0
- By:
- Publication type:
- Article
Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Oral administration of the GnRH antagonist acyline, in a GIPET<sup>®</sup>-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 3, p. 641, doi. 10.1007/s00280-009-1038-1
- By:
- Publication type:
- Article